China’s colorectal cancer treatment market value to exceed $1 billion by 2023, says GlobalData
Posted: 18 February 2015 |
The Chinese treatment market for colorectal cancer will expand almost fourfold in value from an estimated $259 million in 2013 to $1.05 billion by 2023, at an impressive Compound Annual Growth Rate of 15.1%, according to research and consulting firm GlobalData…
The Chinese treatment market for colorectal cancer (CRC) will expand almost fourfold in value from an estimated $259 million in 2013 to $1.05 billion by 2023, at an impressive Compound Annual Growth Rate (CAGR) of 15.1%, according to research and consulting firm GlobalData.
The company’s latest report* states that this increase, which will make China the third largest global market for CRC treatment behind the US and Japan, will be driven by increasing disease incidence in urban populations, rising numbers of people covered by private health insurance and improved access to branded biologicals.
However, Fenix Leung, DPhil, GlobalData’s Analyst covering Oncology and Hematology, says that growth will be stymied by the patent expiration of Avastin, the leading drug in the Chinese CRC treatment market, and the slower uptake of pipeline therapies.
Leung explains: “There is often a delay in new drug launches in China relative to the US, Europe and Japan, due to an extended approval process by the China Food and Drug Administration (CFDA). For drugs that have not undergone clinical trials in Chinese patients prior to their application submission, the CFDA can require additional safety studies to be conducted in China before accepting a registration application.
“As nintedanib, Cyramza, and Imprime PGG are examples of pipeline products that have not undergone clinical trials in China, we do not expect them to launch in this market during the forecast period.”
Despite this, GlobalData predicts the market entry of four additional drugs by 2023. These include Amgen/Takeda’s Vectibix, Bayer’s Stivarga, Sanofi’s Zaltrap, and Taiho Pharmaceutical’s Lonsurf.
Leung continues: “These agents will garner combined revenues of $334 million in 2023, representing 32% of the Chinese CRC treatment market.
“Stivarga is expected to be the clear market leader of these drugs, with peak-year sales of $291 million expected in 2023. This will follow its label extension as an adjuvant treatment for CRC patients with resected liver metastases and prior chemotherapy neoadjuvant/adjuvant treatment,” the analyst concludes.
*PharmaPoint: Colorectal Cancer – Global Drug Forecast and Market Analysis to 2023
